After Years of Resistance, NPPA Finally Allows GSK to Discontinue Grisovin FP

New Delhi: In a significant regulatory shift, the National Pharmaceutical Pricing Authority (NPPA) has revoked its earlier direction that had compelled GlaxoSmithKline Pharmaceuticals (GSK) to continue manufacturing the antifungal drug Grisovin FP 250 mg containing "Griseofulvin."

After more than four years of being barred from exiting the market, GSK has finally been granted permission to discontinue the product.

This came after the authorities deliberated on the Form-IV intimation by GlaxoSmithkline Pharmaceutical Limited (GSK) for discontinuation of the scheduled formulation, Grisovin FP 250mg Tablet containing Griseofulvin, at the 138th Meeting of Authority under DPCO, 2013 held on 30.10.2025.

The Authority deliberated upon the matter in detail and noted that GlaxoSmithKline Pharma